Molecular Biomarkers of Response to Radiation Therapy in Breast Cancer
Launched by INSTITUTE OF ONCOLOGY LJUBLJANA · Oct 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain genetic and molecular markers in breast cancer patients can help predict how well they will respond to radiation therapy. By identifying these markers, the goal is to personalize radiation treatment for breast cancer in the future, making it more effective for each individual patient.
To be eligible for this study, participants must be female patients diagnosed with ductal carcinoma in situ (DCIS) who are recommended to receive radiation therapy after surgery. Unfortunately, those who are undergoing other specific cancer treatments are not able to join. If you participate in this study, you'll be contributing to important research that could lead to better and more tailored treatment options for breast cancer patients in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast cancer patients with DCIS with an indication for adjuvant radiation therapy
- Exclusion Criteria:
- • Any specific systemic oncological therapy
About Institute Of Oncology Ljubljana
The Institute of Oncology Ljubljana is a leading clinical research institution dedicated to advancing cancer care through innovative research and comprehensive treatment strategies. As a prominent center in Slovenia, it specializes in a multidisciplinary approach to oncology, integrating cutting-edge clinical trials with state-of-the-art diagnostic and therapeutic services. The institute collaborates with national and international partners to enhance cancer prevention, diagnosis, and treatment, aiming to improve patient outcomes and contribute to the global understanding of cancer. With a commitment to excellence in patient care and research, the Institute of Oncology Ljubljana plays a pivotal role in shaping the future of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ljubljana, , Slovenia
Patients applied
Trial Officials
Tanja Marinko, MD, PhD
Principal Investigator
Institute of Oncology Ljubljana
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported